|
Date/Time |
Lecturer |
Affiliation |
Topic |
|
9/19/06 |
Stephen Howell, MD
Prof. Medicine |
UCSD |
Introduction to Cancer Therapeutics Development |
|
9/26/06
|
David Shalinsky, PhD
Assoc. Director, Translational Medicine |
Pfizer Pharmaceutical |
Basics of Preclinical Drug Development-Oncology Drug Development in Industry |
|
10/3/06 |
John Longnecker, PhD
President & CEO |
Favrille Pharmaceuticals |
Development of a Novel Immunotherapy for B-cell non-Hodgkin's Lymphoma: From Conception to Completion of Pivotal Registration Trials |
|
10/17/06 |
David Cheresh, PhD
Prof. Pathology |
UCSD |
Integrins and Their Signaling Activities as Targets for Cancer Drug Development |
|
10/24/06 |
Steven Dowdy, PhD
Prof. CMM |
UCSD |
Developing Novel Drug Targeting Systems |
|
10/31/06 |
William Rice PhD
President & CEO |
Cylene Pharmaceuticals |
Discovery, Development and Commercialization of Targeted Small-Molecule Oncology Drugs: A Biotech Perspective |
|
11/07/06 |
Edmund Capparelli, MD
Prof. Pediatrics |
UCSD |
PK Components of Drug Development |
|
11/21/06 |
Michael Bouvet, MD
Prof. Surgery |
UCSD |
Efficacy in Murine Tumor Models |
|
11/28/06 |
Jean Wang, MD
Prof. Medicine |
UCSD |
Genetic Determinants of Drug Sensitivity |
11/30/06 |
Katherine Bowdish, PhD
President |
Alexion Antibody
Technologies |
Harnessing the Immune System for the Treatment of Tumors: Discovery, Pre-clinical Development and Transitioning to the Clinic of a Novel Anti-Cancer Antibody that Blocks Immune Suppression |
|
12/05/06 |
Judy Varner, PhD
Assoc. Prof. Med. |
UCSD |
Vascular and Lymphatic Endothelial Cells as Novel Drug Targets |
1/08/07 |
Lyle Arnold, PhD
VP Research |
Gen-Probe |
Nucleic Acid Diagnostics for Cancer and Infectious Disease Detection |
1/09/07 |
Richard Klemke, MD
Prof. Pathology |
UCSD |
Modeling Human Cancer Progression in Optically Transparent Zebrafish |
|
1/16/07 |
William Fenical, PhD
Dir-CMBB/Prof |
UCSD |
Deep Ocean Bacteria: A New Resource for the Discovery of Anticancer Therapeutics and Chemopreventive Agents |
|
1/23/07 |
Charles Carrera, MD
Assoc. Clin. Prof. Med. |
UCSD |
Regulatory Affairs |
|
1/29/07 |
Stephen Burley, MD, PhD
CSO, SVP Research. |
SGX Pharmaceuticals |
Fragment-based Discovery of BCR-ABL Inhibitors for Treatment of Chronic Myelogenous Leukemia |
|
1/30/07 |
Geert Schmidt-Schoenbein, PhD
Prof. Bioengineering |
UCSD |
Inflammatory Mechanisms: The Autodigestion Hypothesis |
|
2/27/07 |
David R. Webb, PhD
VP Research |
Signal
Pharmaceuticals |
Developing Novel Drugs for Cancer-An Atypical Example: Thalomid and Revlimid |
3/23/07 |
Steven D. Reich, MD
Chief Medical Officer |
Attenuon Pharmaceuticals |
Developing a Clinical Operating Plan: ATN-224 as an Example
|
4/25/07 |
Han-Ming Shen, MD, PhD
Assistant Professor
|
Yong-Loo Lin SOM-Singapore |
The Critical Role of JNK in Non-apoptotic Cell Death Mediated by Reactive Oxygen/Nitrogen Species |
4/30/07 |
Mitchell Reff, PhD
VP Discovery Oncology
|
Biogen Idec |
Oncology Discovery and Development: Challenges and Opportunities |
5/15/07 |
Wendell Wierenga
Exec. VP research
|
Ambit Biosciences |
The Role of Kinase Inhibitors in Cancer Drug Discovery/Development, Exemplifying the Ambit KinomeScan Technology |
6/19/07 |
Jon Holmlund, MD
CMO
|
Ascenta Therapeutics |
Development of Small Molecule Inhibitors of Anti-apoptosis Pathways for the Treatment of Patients with Cancer
Venue Change: Goldberg Auditorium
|
